@NP	Part of them	987
@NP	Part	987
@NP	them	995
@NP	neuropathic pain which presents unique challenges to clinicians	1008
@NP	neuropathic pain	1008
@NP	unique challenges	1040
@NP	clinicians	1061
@NP	andthere	1073
@NP	no effective approach for the treatment up to now	1085
@NP	no effective approach	1085
@NP	the treatment up to now	1111
@NP	the treatment	1111
@NP	now	1131
@NP	Neural stem cells	1136
@NP	NSCs	1155
@NP	transplantation	1161
@NP	a promising and an effective method	1180
@NP	a promising	1180
@NP	an effective method	1196
@NP	the treatment of SCI	1241
@NP	the treatment	1241
@NP	SCI	1258
@NP	a mainproblem	1271
@NP	the low survival of NSCs in traumatic milieu in host spinal cords	1288
@NP	the low survival	1288
@NP	NSCs in traumatic milieu in host spinal cords	1308
@NP	NSCs	1308
@NP	traumatic milieu in host spinal cords	1316
@NP	traumatic milieu	1316
@NP	host spinal cords	1336
@NP	the effect of NSCs onsensory function	1359
@NP	the effect	1359
@NP	NSCs onsensory function	1373
@NP	NSCs	1373
@NP	onsensory function	1378
@NP	this study	1417
@NP	we	1429
@NP	the effect and underlying molecularmechanism	1445
@NP	co-transplantation	1493
@NP	NSCs	1515
@NP	olfactory ensheathing cells	1525
@NP	OECs	1554
@NP	sensory functionalimprovement	1563
@NP	the measurement of thermal and mechanical stimuli	1597
@NP	the measurement	1597
@NP	thermal and mechanical stimuli	1616
@NP	NSCs grafts	1648
@NP	sensoryfunction	1670
@NP	SCI rats	1689
@NP	OECs	1705
@NP	hyperalgesia	1717
@NP	the tail flick latency -LRB- TFL -RRB- and pawwithdraw latency -LRB- PWL -RRB-	1744
@NP	the tail flick latency	1744
@NP	TFL	1768
@NP	pawwithdraw latency	1777
@NP	PWL	1798
@NP	p < 0.05	1804
@NP	p	1804
@NP	< 0.05	1806
@NP	<	1806
@NP	0.05	1808
@NP	Co-transplantation	1815
@NP	NSCs survival	1848
@NP	thehyperalgesia triggered by OECs	1876
@NP	thehyperalgesia	1876
@NP	OECs	1905
@NP	This	1911
@NP	a significant improvement in sensory function.Moreover	1937
@NP	a significant improvement	1937
@NP	sensory function.Moreover	1966
@NP	NGF expression	1993
@NP	the spinal cord of co-transplantation rats.The present findings	2041
@NP	the spinal cord	2041
@NP	co-transplantation rats.The present findings	2060
@NP	co-transplantation of NSCs with OECs	2120
@NP	co-transplantation	2120
@NP	NSCs with OECs	2142
@NP	NSCs	2142
@NP	OECs	2152
@NP	sensory functionand	2171
@NP	the possible mechanism	2191
@NP	NGF downregulation	2229
@NP	rats with SCI	2251
@NP	rats	2251
@NP	SCI	2261
@NP	This	2266
@NP	some newindications for the treatment of SCI	2280
@NP	some newindications	2280
@NP	the treatment of SCI	2304
@NP	the treatment	2304
@NP	SCI	2321
@NP	future clinic cell therapy trial	2328
@NP	IntroductionSpinal cord injury -LRB- SCI -RRB-	2366
@NP	IntroductionSpinal cord injury	2366
@NP	SCI	2398
@NP	paraplegia , orquadriplegia	2423
@NP	paraplegia	2423
@NP	orquadriplegia	2435
@NP	significant pain	2468
@NP	degeneration ofaxons	2492
@NP	loss of neurons	2514
@NP	loss	2514
@NP	neurons	2522
@NP	glia , demyelination and injury-inducedchanges in neuronal excitability	2534
@NP	glia , demyelination and injury-inducedchanges	2534
@NP	neuronal excitability	2583
@NP	Many strategies	2606
@NP	functional improvement and pain management includingsurgical	2647
@NP	functional improvement and pain management	2647
@NP	medical care , pharmacological , neurophysiologicaland technological approaches	2712
@NP	medical care	2712
@NP	pharmacological , neurophysiologicaland technological approaches	2726
@NP	current clinical therapiesfor SCI	2800
@NP	current clinical therapiesfor	2800
@NP	SCI	2830
@NP	Recent studies	2847
@NP	the cellulartransplant therapy	2878
@NP	a promising approach	2916
@NP	the damaged cells	2953
@NP	neuroprotective and neuroregenera-tive repair following SCI	2986
@NP	neuroprotective and neuroregenera-tive repair	2986
@NP	SCI	3042
@NP	Neural stem cells -LRB- NSCs -RRB-	3047
@NP	Neural stem cells	3047
@NP	NSCs	3066
@NP	the abilityto self-renew	3077
@NP	neurons , astro-cytes , and oligodendrocytes	3143
@NP	11,12,24,28 -RSB-	3187
@NP	it	3210
@NP	awayfrom practical clinic usage	3220
@NP	its limited survival in vivo	3263
@NP	its limited survival	3263
@NP	vivo	3287
@NP	new strategies	3320
@NP	the survival	3347
@NP	NSCs	3375
@NP	injured spinal cord	3383
@NP	the other hand	3407
@NP	somerecent studies and clinical trials	3423
@NP	somerecent studies	3423
@NP	clinical trials	3446
@NP	olfactory ensheathingcells -LRB- OECs -RRB-	3476
@NP	olfactory ensheathingcells	3476
@NP	OECs	3504
@NP	a better candidate for cell based regener-ative therapies -LSB- 19,23 -RSB-	3517
@NP	a better candidate	3517
@NP	cell based regener-ative therapies -LSB- 19,23 -RSB-	3540
@NP	cell	3540
@NP	regener-ative therapies -LSB- 19,23 -RSB-	3551
@NP	regener-ative therapies	3551
@NP	19,23 -RSB-	3576
@NP	Recent studies	3584
@NP	OECs	3613
@NP	axonal regrowth	3639
@NP	astrocyte reactivity , increase angiogenesis	3665
@NP	astrocyte reactivity	3665
@NP	increase angiogenesis	3686
@NP	glial scar leading	3721
@NP	functionalrecovery	3743
@NP	experimental models of SCI inrodents	3785
@NP	experimental models	3785
@NP	SCI inrodents	3808
@NP	19,25,31,32 -RSB-	3823
@NP	OECs	3837
@NP	transplant-mediatedrepair of spinal cord trauma	3861
@NP	transplant-mediatedrepair	3861
@NP	spinal cord trauma	3890
@NP	non-repairing foci	3912
@NP	chronic multiple sclerosis	3956
@NP	-LSB- 3,15 -RSB-	3984
@NP	controversyexists	4001
@NP	13,29 -RSB-	4020
@NP	it	4028
@NP	implanted OECs	4051
@NP	functional recovery and axonal regrowth	4079
@NP	functional recovery	4079
@NP	axonal regrowth	4103
@NP	lesions of theCNS or peripheral nervous system -LRB- PNS -RRB- -LSB- 10,14 -RSB-	4125
@NP	lesions of theCNS	4125
@NP	lesions	4125
@NP	theCNS	4136
@NP	peripheral nervous system -LRB- PNS -RRB- -LSB- 10,14 -RSB-	4146
@NP	peripheral nervous system -LRB- PNS -RRB-	4146
@NP	peripheral nervous system	4146
@NP	PNS	4173
@NP	10,14 -RSB-	4179
@NP	aftertransplantation , OECs	4201
@NP	aftertransplantation	4201
@NP	OECs	4223
@NP	various kinds of neurotrophinsso	4240
@NP	various kinds	4240
@NP	neurotrophinsso	4257
@NP	they	4278
@NP	a source	4287
@NP	neurotrophic factors	4299
@NP	NTF	4321
@NP	whichinclude nerve growth factor -LRB- NGF -RRB-	4326
@NP	whichinclude nerve growth factor	4326
@NP	NGF	4360
@NP	brain	4366
@NP	neurotrophic fac-tor -LRB- BDNF -RRB-	4380
@NP	neurotrophic fac-tor	4380
@NP	BDNF	4402
@NP	Neurotrophin-3 -LRB- NT-3 -RRB-	4409
@NP	Neurotrophin-3	4409
@NP	NT-3	4425
@NP	Neurotrophin-4 -LRB- NT-4 -RRB-	4432
@NP	Neurotrophin-4	4432
@NP	NT-4	4448
@NP	Cilliaryneurotrophic factor -LRB- CNTF -RRB-	4455
@NP	Cilliaryneurotrophic factor	4455
@NP	CNTF	4484
@NP	platelet-derived growth factor -LRB- PDGF -RRB-	4491
@NP	platelet-derived growth factor	4491
@NP	PDGF	4523
@NP	neuropeptide Y.	4533
@NP	neuropeptide	4533
@NP	Y.	4546
@NP	The secretion of these neurotrophic factorsmay	4549
@NP	The secretion	4549
@NP	these neurotrophic factorsmay	4566
@NP	the capacities of OECs	4604
@NP	the capacities	4604
@NP	OECs	4622
@NP	the regenerativeprocess	4641
@NP	cellular bridges	4676
@NP	axonal regenerationacross	4702
@NP	the repair site	4728
@NP	the survival of damaged axons -LSB- 7,9,26,27 -RSB-	4756
@NP	the survival	4756
@NP	damaged axons -LSB- 7,9,26,27 -RSB-	4772
@NP	damaged axons	4772
@NP	7,9,26,27 -RSB-	4786
@NP	increase the survival of grafts	4809
@NP	increase	4809
@NP	the survival of grafts	4818
@NP	the survival	4818
@NP	grafts	4834
@NP	NSCs	4867
@NP	this study	4876
@NP	we	4888
@NP	the effect ofco-transplantation of NSCs	4906
@NP	the effect ofco-transplantation	4906
@NP	NSCs	4941
@NP	OECs on sensory function improve-ment	4951
@NP	OECs	4951
@NP	sensory function improve-ment	4959
@NP	rats with spinal cord transection	4992
@NP	rats	4992
@NP	spinal cord transection	5002
@NP	The mechanical andthermal hyperalgesia behaviors of rats with SCI	5027
@NP	The mechanical andthermal hyperalgesia behaviors	5027
@NP	rats with SCI	5079
@NP	rats	5079
@NP	SCI	5089
@NP	co-transplantation	5116
@NP	we	5141
@NP	the underlying mecha-nism	5153
@NP	Methods 2.1 .	5184
@NP	Subjects and grouping Experiments	5197
@NP	Subjects	5197
@NP	grouping Experiments	5210
@NP	adult female Sprague-Dawleyrats weighing 180	5249
@NP	adult female Sprague-Dawleyrats	5249
@NP	180	5290
@NP	250 g , ranging in age from 90 to 120 days ,	5294
@NP	250 g	5294
@NP	age	5312
@NP	90 to 120 days	5321
@NP	the Animal Center of the Si chuan University	5349
@NP	the Animal Center	5349
@NP	the Si chuan University	5370
@NP	Standardrodent food and water	5395
@NP	Standardrodent food	5395
@NP	water	5419
@NP	available ad libitum	5430
@NP	Room temperatureand relative humidity were maintained at 22 ±	5452
@NP	Room temperatureand	5452
@NP	relative humidity	5472
@NP	22 ±	5509
@NP	0.5 ◦ C and 40	5514
@NP	0.5 ◦ C	5514
@NP	40	5524
@NP	50 % , respectively	5527
@NP	50 %	5527
@NP	A 12-h light/12-h dark cycle	5545
@NP	testingwas	5587
@NP	the light phase	5611
@NP	a blind manner in which theobservers were not informed about the treatment	5630
@NP	a blind manner	5630
@NP	theobservers	5654
@NP	the treatment	5691
@NP	Animals	5706
@NP	at least three times	5726
@NP	any testing	5754
@NP	Ani-mal treatments	5781
@NP	pain or discomfortin accordance	5829
@NP	current protocols	5866
@NP	compliance with relatedlaws	5887
@NP	compliance	5887
@NP	relatedlaws	5903
@NP	the current guidelines	5919
@NP	the National Institute of HealthGuide and Use	5945
@NP	the National Institute	5945
@NP	HealthGuide and Use	5971
@NP	Laboratory Animals , USA	5994
@NP	Laboratory Animals	5994
@NP	USA	6014
@NP	the different treat-ments	6023
@NP	the rats	6050
@NP	five experimental groups	6077
@NP	eachgroup	6106
@NP	8 animals	6117
@NP	RT-PCR and WB analysis	6141
@NP	10animals	6169
@NP	behavioral test	6203
@NP	mechan-ical stimulus	6229
@NP	thermal stimulus which was then processed forimmunohistochemical staining	6254
@NP	thermal stimulus	6254
@NP	forimmunohistochemical staining	6296
@NP	2.2	6329
@NP	Spinal cord transection and cell grafting Rats	6334
@NP	Spinal cord transection	6334
@NP	cell grafting Rats	6362
@NP	40 -- 60 mg kg − 1 of pento-barbital	6411
@NP	40	6411
@NP	60 mg kg −	6414
@NP	1 of pento-barbital	6423
@NP	1	6423
@NP	pento-barbital	6428
@NP	supine	6459
@NP	Laminectomies at 7	6467
@NP	Laminectomies	6467
@NP	7	6484
@NP	9th thoracicvertebral levels were performed under a surgical microscope	6486
@NP	9th thoracicvertebral levels	6486
@NP	a surgical microscope	6536
@NP	Thedura	6559
@NP	the spinal cord	6582
@NP	sharp sterilized fine scissors	6629
@NP	The rostral and caudal stumpswere	6661
@NP	The rostral	6661
@NP	caudal stumpswere	6677
@NP	complete transection	6712
@NP	The body	6734
@NP	temperatureof rats	6743
@NP	37 ◦ C	6780
@NP	the operation.Cell suspensions	6792
@NP	a concentration of3	6840
@NP	× 105NSCs/µl , 3 × 105OECs/µl and 3 × 105NSCs	6860
@NP	× 105NSCs/µl	6860
@NP	3 × 105OECs/µl	6874
@NP	3 × 105NSCs	6893
@NP	OECs/µl inculture medium -LRB- Invitrogen -RRB-	6907
@NP	OECs/µl inculture medium	6907
@NP	Invitrogen	6933
@NP	ice for transplan-tation	6963
@NP	ice	6963
@NP	transplan-tation	6971
@NP	the lesion	7018
@NP	the cells	7030
@NP	gelatin then transplanted into injury site	7059
@NP	gelatin	7059
@NP	injury site	7090
@NP	Aftersurgery , the incision	7103
@NP	Aftersurgery	7103
@NP	the incision	7117
@NP	the midline	7148
@NP	the ratswere	7164
@NP	access	7219
@NP	foodand water	7229
@NP	ad libitum in isolated cages	7246
@NP	ad libitum	7246
@NP	isolated cages	7260
@NP	Bladders of animals	7276
@NP	Bladders	7276
@NP	animals	7288
@NP	twice a day	7317
@NP	administrated penicillin	7333
@NP	3days	7362
@NP	the immunoreaction	7379
@NP	cyclosporine A -LRB- 5 mg ml − 1 -RRB-	7399
@NP	cyclosporine A	7399
@NP	5 mg ml − 1	7415
@NP	5 mg ml −	7415
@NP	1	7423
@NP	twice a day	7453
@NP	cell transplantation	7472
@NP	1 week -LRB- once a day -RRB-	7519
@NP	1 week	7519
@NP	once a day	7527
@NP	once	7527
@NP	a day	7532
@NP	animals	7544
@NP	Part of the rats	7570
@NP	Part	7570
@NP	the rats	7578
@NP	2 weeks for RT-PCR , and4 weeks for behavior and morphology observation	7607
@NP	2 weeks	7607
@NP	RT-PCR , and4 weeks for behavior and morphology observation	7619
@NP	RT-PCR	7619
@NP	and4 weeks for behavior and morphology observation	7627
@NP	and4 weeks	7627
@NP	behavior and morphology observation	7642
@NP	2.3	7679
@NP	Behavioral study 2.3.1 .	7684
@NP	Behavioral study	7684
@NP	2.3.1	7701
@NP	Thermal stimulus Tail flick latencies -LRB- TFLs -RRB-	7708
@NP	Thermal stimulus Tail flick latencies	7708
@NP	TFLs	7747
@NP	a TAIL FLICK UNIT7360 -LRB- Ugo Basile , Comerio , Italy -RRB- apparatus	7770
@NP	Ugo Basile	7793
@NP	Comerio	7805
@NP	Italy	7814
@NP	a beam of light	7841
@NP	a beam	7841
@NP	light	7851
@NP	the dorsal surface of the tail	7872
@NP	the dorsal surface	7872
@NP	the tail	7894
@NP	the time that it took the rat to withdraw its tail from the noxious stimulus	7908
@NP	the time	7908
@NP	it	7922
@NP	the rat to withdraw its tail from the noxious stimulus	7930
@NP	its tail	7950
@NP	the noxious stimulus	7964
@NP	The rats	7999
@NP	the rat holder with a tail exitport	8027
@NP	the rat holder	8027
@NP	a tail exitport	8047
@NP	the measurement	8070
@NP	The tests	8087
@NP	5 times -LRB- with a 2-min interval -RRB- at each time point	8112
@NP	5 times -LRB- with a 2-min interval -RRB-	8112
@NP	a 2-min interval	8125
@NP	each time point	8146
@NP	The cut-off	8163
@NP	at15 s	8183
@NP	the maximum possible effect in order	8193
@NP	the maximum possible effect	8193
@NP	order	8224
@NP	tissue damage	8239
@NP	the tail	8256
@NP	A rat that did not flick by 10 s	8266
@NP	A rat	8266
@NP	flick	8285
@NP	10 s	8294
@NP	2.3.2	8334
@NP	Mechanical stimulus Mechanical nociceptive thresholds	8341
@NP	Mechanical stimulus	8341
@NP	Mechanical nociceptive thresholds	8361
@NP	theDynamic Plantar Aesthesiometer	8415
@NP	37215 -LRB- Ugo Basile , Comerio , Italy -RRB-	8449
@NP	37215	8449
@NP	Ugo Basile	8456
@NP	Comerio	8468
@NP	Italy	8476
@NP	Rats	8484
@NP	3 days	8506
@NP	testing	8520
@NP	Each rat	8529
@NP	a towel during the test	8571
@NP	a towel	8571
@NP	the test	8586
@NP	The rat	8596
@NP	shindpaw	8604
@NP	a wedge-shaped blunt piston andplinth	8632
@NP	Incremental pressure	8671
@NP	the pedal	8719
@NP	the blunt piston	8729
@NP	the dorsal surface of the hind paw	8758
@NP	the dorsal surface	8758
@NP	the hind paw	8780
@NP	a screw that moved the slide along the scale	8810
@NP	a screw	8810
@NP	the slide	8829
@NP	the scale	8845
@NP	Abrisk foot withdrawal	8856
@NP	the hind leg along with constantly increas-ing pressure	8882
@NP	the hind leg	8882
@NP	constantly increas-ing pressure	8906
@NP	the measurement	8949
@NP	the final pressure	8970
@NP	the scale	9001
@NP	grams	9026
@NP	The cutoff pressurewas 500 g.	9034
@NP	The cutoff pressurewas	9034
@NP	500 g.	9057
@NP	The measurements	9064
@NP	4 times	9096
@NP	15 sintervals	9107
@NP	their mean	9126
@NP	calculations	9150
@NP	An increasein paw pressure threshold	9164
@NP	mechanical antinoci-ception	9220
@NP	An examiner	9249
@NP	the treatment protocol performedall behavioral experiments	9272
@NP	The raw data	9332
@NP	usingmean ± SEM	9359
@NP	2.4	9376
@NP	Statistical analysis All statistical analyses	9381
@NP	Statistical analysis	9381
@NP	All statistical analyses	9403
@NP	the statisticalsoftware SPSS11 .0	9449
@NP	Data	9483
@NP	means	9509
@NP	standarddeviations	9517
@NP	A Students t-test	9537
@NP	two sets of datawere	9574
@NP	two sets	9574
@NP	datawere	9586
@NP	three sets of data	9610
@NP	three sets	9610
@NP	data	9624
@NP	one-wayANOVA with a LSD-t	9645
@NP	one-wayANOVA	9645
@NP	a LSD-t	9663
@NP	equal variance	9672
@NP	A p valueless than 0.05	9706
@NP	A p	9706
@NP	0.05	9725
@NP	statistical significance	9749
@NP	Results Fig. 1 .	9779
@NP	Results	9779
@NP	Fig. 1	9787
@NP	Morphology of NSCs and OECs and their identification in vitro .	9795
@NP	Morphology	9795
@NP	NSCs and OECs and their identification	9809
@NP	NSCs and OECs	9809
@NP	their identification	9827
@NP	vitro	9851
@NP	Neurosphere at day 7	9867
@NP	Neurosphere	9867
@NP	day 7	9882
@NP	A -LRB- natural light -RRB-	9901
@NP	A	9901
@NP	natural light	9904
@NP	B	9920
@NP	GFP expression under fluorescentmicroscopy	9923
@NP	GFP expression	9923
@NP	fluorescentmicroscopy	9944
@NP	C -LRB- nestin positive , confirming NSCs -RRB-	9972
@NP	C	9972
@NP	nestin positive , confirming NSCs	9975
@NP	nestin positive	9975
@NP	confirming NSCs	9992
@NP	Part of NSCs	10010
@NP	Part	10010
@NP	NSCs	10018
@NP	neural differentiation -LRB- D , arrow -RRB-	10032
@NP	neural differentiation	10032
@NP	astrocytes -LRB- E , arrow -RRB-	10067
@NP	astrocytes	10067
@NP	E , arrow	10079
@NP	E	10079
@NP	arrow	10082
@NP	oligodendrocytes -LRB- F , arrow -RRB-	10093
@NP	oligodendrocytes	10093
@NP	F , arrow	10111
@NP	F	10111
@NP	arrow	10114
@NP	respectively.G	10122
@NP	morphology of OECs	10144
@NP	morphology	10144
@NP	OECs	10158
@NP	H	10173
@NP	p75 positive OECs	10182
@NP	I	10201
@NP	the nuclear labeled OECs with Hoechst 33342	10213
@NP	the nuclear	10213
@NP	OECs	10233
@NP	Hoechst 33342	10243
@NP	Bar	10258
@NP	20 µm , showing in I.	10264
@NP	20 µm	10264
@NP	I.	10282
@NP	Fig. 2 .	10286
@NP	Fig.	10286
@NP	2	10291
@NP	Effect of OECs on NSCs survival and proliferation in vitro .	10294
@NP	Effect	10294
@NP	OECs	10304
@NP	NSCs survival and proliferation in vitro	10312
@NP	NSCs survival and proliferation	10312
@NP	A	10354
@NP	the proliferation of NSCs cultured alone	10363
@NP	the proliferation	10363
@NP	NSCs cultured alone	10384
@NP	NSCs	10384
@NP	co-culture group	10408
@NP	the proliferation	10426
@NP	the neurosphereincreased significantly in B -LRB- Bar = 50 µm -RRB- ; C	10447
@NP	the neurosphereincreased significantly in B -LRB- Bar = 50 µm -RRB-	10447
@NP	B	10489
@NP	Bar = 50 µm	10492
@NP	Bar =	10492
@NP	50 µm	10498
@NP	C	10506
@NP	the number of the neurosphere	10515
@NP	the number	10515
@NP	the neurosphere	10529
@NP	co-culturing	10561
@NP	D	10575
@NP	the diameter	10584
@NP	the size of the neurosphere	10600
@NP	the size	10600
@NP	the neurosphere	10612
@NP	p <	10643
@NP	p	10643
@NP	<	10645
@NP	0.05	10647
@NP	Fig. 4 .	10655
@NP	Fig.	10655
@NP	4	10660
@NP	Changes of NGF protein in each group .	10663
@NP	Changes	10663
@NP	NGF protein	10674
@NP	each group	10689
@NP	Electrophoresis band of NGF mRNA products	10701
@NP	Electrophoresis band	10701
@NP	NGF mRNA products	10725
@NP	RT-PCR was shown in A	10757
@NP	RT-PCR	10757
@NP	in A	10774
@NP	the quantitative analysis	10784
@NP	shownin B.	10814
@NP	Co-transplantation	10825
@NP	NGF mRNA expression	10854
@NP	NSCs or OECs grafts	10879
@NP	NSCs	10879
@NP	OECs grafts	10887
@NP	NGF level	10914
@NP	C , indicated from Western blotting	10937
@NP	C	10937
@NP	Western blotting	10955
@NP	Quantitativeanalysis	10973
@NP	D.	11007
@NP	NGF	11010
@NP	co-transplantation	11048
@NP	NSCs and OECs	11070
@NP	control	11104
@NP	group -LRB- NSCs or OECs grafts -RRB- -LRB- * , **	11112
@NP	group -LRB- NSCs or OECs grafts -RRB- -LRB- * ,	11112
@NP	group	11112
@NP	NSCs or OECs grafts	11119
@NP	<	11149
@NP	3.1	11159
@NP	Identification and differentiation	11164
@NP	NSCs and OECs in vitro NSCs and OECs from the 3rd passage	11202
@NP	NSCs and OECs	11202
@NP	NSCs and OECs from the 3rd passage	11225
@NP	NSCs and OECs	11225
@NP	the 3rd passage	11244
@NP	immuno-histochemistry	11275
@NP	specific markers , known as nestin and p75 , respectively	11303
@NP	specific markers	11303
@NP	nestin and p75	11330
@NP	the single cellular culture group	11363
@NP	the free-floatingneurospheres	11398
@NP	1	11455
@NP	day	11457
@NP	primary culturewith	11461
@NP	little morphological evidence of differentiation	11481
@NP	little morphological evidence	11481
@NP	differentiation	11514
@NP	the number and volume of neurospheres	11547
@NP	the number and volume	11547
@NP	neurospheres	11572
@NP	someof	11596
@NP	hundreds of cells	11619
@NP	hundreds	11619
@NP	cells	11631
@NP	the 7th day of culture -LRB- Fig. 1A and B -RRB-	11640
@NP	the 7th day	11640
@NP	culture -LRB- Fig. 1A and B -RRB-	11655
@NP	culture	11655
@NP	Fig. 1A and B	11663
@NP	Fig. 1A	11663
@NP	B	11675
@NP	These neurospheres	11679
@NP	Nestin	11703
@NP	they	11741
@NP	NSCs -LRB- Fig. 1C -RRB-	11751
@NP	NSCs	11751
@NP	Fig. 1C	11757
@NP	passage with 10 % FBS medium	11773
@NP	passage	11773
@NP	10 % FBS medium	11786
@NP	neurospheres	11801
@NP	some GFAP and a few NeuNor APC	11824
@NP	some GFAP	11824
@NP	a few NeuNor APC	11838
@NP	Fig. 1D -- F	11871
@NP	Fig. 1D	11871
@NP	F	11879
@NP	The morphology of OECs	11882
@NP	The morphology	11882
@NP	OECs	11900
@NP	andstuck	11936
@NP	the bottom	11948
@NP	1 day	11965
@NP	day 3	11975
@NP	the predominant cellmorphology of OECs	11982
@NP	the predominant cellmorphology	11982
@NP	OECs	12016
@NP	a spindle-like morphology	12025
@NP	two orthree processes , or a flat appearance -LRB- Fig. 1G -RRB-	12056
@NP	two orthree processes	12056
@NP	a flat appearance	12082
@NP	Fig. 1G	12101
@NP	Fig. 1H	12111
@NP	the dis-play	12125
@NP	p75 immunoreactivity	12141
@NP	some flattenedfibroblast-like and astrocyte-like morphologies	12184
@NP	spindle shaped cells	12265
@NP	Immunostaining showedthat at least 95 % of cells in 3	12306
@NP	Immunostaining showedthat	12306
@NP	at least 95 % of cells in 3	12332
@NP	at least 95 %	12332
@NP	cells in 3	12348
@NP	cells	12348
@NP	3	12357
@NP	7 days	12359
@NP	cultures	12366
@NP	p75 antigen , which confirmed that they are OECs -LRB- Fig. 1G and H -RRB-	12385
@NP	p75 antigen	12385
@NP	they	12418
@NP	OECs -LRB- Fig. 1G and H -RRB-	12427
@NP	OECs	12427
@NP	Fig. 1G and H	12433
@NP	Fig. 1G	12433
@NP	H	12445
@NP	The Hoechst3342	12449
@NP	these OECs	12477
@NP	blue fluorescence	12493
@NP	inFig	12520
@NP	1I .	12527
@NP	3.2	12531
@NP	OECs	12536
@NP	NSCs survival and proliferation in vitro In NSCs co-cultured with OECs group	12551
@NP	NSCs survival	12551
@NP	proliferation in vitro In NSCs co-cultured with OECs group	12569
@NP	NSCs co-cultured with OECs	12595
@NP	NSCs	12595
@NP	OECs	12617
@NP	seven days ' cul-ture	12639
@NP	seven days '	12639
@NP	the number of neurospheres	12661
@NP	the number	12661
@NP	neurospheres	12675
@NP	whichshowed 68.9 ± 15.8 , more than that of single NSCs culture group	12713
@NP	68.9	12725
@NP	that of single NSCs culture	12748
@NP	that	12748
@NP	single NSCs culture	12756
@NP	50.3 ± 9.8	12782
@NP	50.3 ±	12782
@NP	9.8	12789
@NP	the diameter of neurosphere in NSCs co-cultured with OECs group	12805
@NP	neurosphere	12821
@NP	NSCs co-cultured with OECs	12836
@NP	NSCs	12836
@NP	OECs	12858
@NP	154.1 ± 69.3 Pixels	12870
@NP	154.1 ±	12870
@NP	69.3 Pixels	12878
@NP	significantlybigger	12895
@NP	that of single NSCs cultured group -LRB- 109.8 ± 50.5 Pix-els -RRB-	12920
@NP	that	12920
@NP	single NSCs cultured group -LRB- 109.8 ± 50.5 Pix-els -RRB-	12928
@NP	single NSCs	12928
@NP	group -LRB- 109.8 ± 50.5 Pix-els -RRB-	12949
@NP	group	12949
@NP	109.8 ± 50.5 Pix-els	12956
@NP	109.8	12956
@NP	± 50.5 Pix-els	12962
@NP	± 50.5	12962
@NP	Pix-els	12969
@NP	These results	12979
@NP	co-culture	13005
@NP	not only thenumber of NSCs but also the size of NSCs	13026
@NP	thenumber of NSCs	13035
@NP	thenumber	13035
@NP	NSCs	13048
@NP	the size of NSCs	13062
@NP	the size	13062
@NP	NSCs	13074
@NP	OECscould	13096
@NP	survival and proliferation of NSCs -LRB- Fig. 2A -- D -RRB-	13127
@NP	survival and proliferation	13127
@NP	NSCs -LRB- Fig. 2A -- D -RRB-	13157
@NP	NSCs	13157
@NP	Fig. 2A -- D	13162
@NP	Fig. 2A	13162
@NP	D	13170
@NP	3.3	13174
@NP	Transplantation of NSCs and OECs	13179
@NP	Transplantation	13179
@NP	NSCs and OECs	13198
@NP	the sensory function in rats with SCT Mechanical stimulus	13220
@NP	the sensory function	13220
@NP	rats with SCT Mechanical stimulus	13244
@NP	rats	13244
@NP	SCT Mechanical stimulus	13254
@NP	SCT significantly	13290
@NP	SCT	13290
@NP	decreasedPWL compared with sham one	13308
@NP	decreasedPWL	13308
@NP	sham one	13335
@NP	p < 0.01	13345
@NP	p	13345
@NP	< 0.01	13347
@NP	<	13347
@NP	0.01	13349
@NP	OECs	13356
@NP	PWL	13398
@NP	SCT one	13416
@NP	p < 0.05	13425
@NP	p	13425
@NP	< 0.05	13427
@NP	<	13427
@NP	0.05	13429
@NP	co-transplantation of NSCs with OECs	13445
@NP	co-transplantation	13445
@NP	NSCs with OECs	13467
@NP	NSCs	13467
@NP	OECs	13477
@NP	a signif-icantly increase of PWL	13489
@NP	a signif-icantly increase	13489
@NP	PWL	13518
@NP	OECs transplantationgroup -LRB- p < 0.01 -RRB- -LRB- Fig. 3A -RRB-	13539
@NP	OECs transplantationgroup -LRB- p < 0.01 -RRB-	13539
@NP	OECs transplantationgroup	13539
@NP	p < 0.01	13566
@NP	p	13566
@NP	< 0.01	13568
@NP	<	13568
@NP	0.01	13570
@NP	Fig. 3A	13577
@NP	There	13587
@NP	no significant difference betweenco-transplantation group and sham group	13596
@NP	co-transplantation of NSCs with OECs	13691
@NP	co-transplantation	13691
@NP	NSCs with OECs	13713
@NP	NSCs	13713
@NP	OECs	13723
@NP	the recovery ofsensory function.Thermal	13742
@NP	stimulus test	13782
@NP	OECs	13808
@NP	TFL	13847
@NP	OECs	13871
@NP	sensitivity	13896
@NP	SCT rats , p < 0.01	13911
@NP	SCT rats	13911
@NP	p < 0.01	13921
@NP	p <	13921
@NP	p	13921
@NP	0.01	13925
@NP	rats onlysubjected to SCT	13945
@NP	rats	13945
@NP	SCT	13967
@NP	co-transplantation NSCs withOECs	13987
@NP	TFL	14043
@NP	OECs	14062
@NP	transplanta-tion group	14067
@NP	NSCs grafts	14099
@NP	benefit for the improvementof sensory function	14114
@NP	benefit	14114
@NP	the improvementof sensory function	14126
@NP	p	14163
@NP	< 0.05 , Fig. 3B	14165
@NP	<	14165
@NP	0.05	14167
@NP	Fig. 3B	14173
@NP	We	14183
@NP	co-transplantation of NSCs with OECs	14200
@NP	co-transplantation	14200
@NP	NSCs with OECs	14222
@NP	NSCs	14222
@NP	OECs	14232
@NP	the sensoryfunction recovery	14254
@NP	the result	14296
@NP	there	14312
@NP	no significantdifference between co-transplantation group	14321
@NP	no significantdifference	14321
@NP	co-transplantation group	14354
@NP	sham group.The survival of NSCs	14383
@NP	sham group.The survival	14383
@NP	NSCs	14410
@NP	the numberof live cells -LRB- green fluorescent -RRB-	14443
@NP	the numberof live cells	14443
@NP	The cells	14488
@NP	spinal cord	14541
@NP	thelesion site	14579
@NP	Co-transplantation	14595
@NP	the survival ofNSCs	14632
@NP	that in only NSCs transplanted group -LRB- Fig	14672
@NP	that	14672
@NP	only NSCs	14680
@NP	S1	14714
@NP	3.4	14719
@NP	Change	14724
@NP	NGF	14734
@NP	the spinal cord	14741
@NP	co-transplantation Sub-localization for immunopositivity	14767
@NP	co-transplantation Sub-localization	14767
@NP	immunopositivity	14807
@NP	theregions of the lamina I and III	14840
@NP	theregions	14840
@NP	the lamina I and III	14854
@NP	the lamina I	14854
@NP	III	14871
@NP	NGF mRNA positive staining	14880
@NP	NGF mRNA	14880
@NP	the spinal lamina II of the dorsal horn -LRB- Figs	14920
@NP	the spinal lamina II	14920
@NP	the dorsal horn -LRB- Figs	14944
@NP	the dorsal horn -LRB-	14944
@NP	S3	14973
@NP	the effect of co-transplantation	14991
@NP	the effect	14991
@NP	co-transplantation	15005
@NP	theexpression of NGF	15027
@NP	theexpression	15027
@NP	NGF	15044
@NP	RT-PCR	15049
@NP	samples 2 weeksafter co-transplantation	15075
@NP	samples	15075
@NP	2 weeksafter co-transplantation	15083
@NP	NSCs orOECs transplantation rats	15144
@NP	NGF mRNA expression inco-transplantation rats	15188
@NP	the spinal cord of rats -LRB- Fig. 4A and B -RRB-	15250
@NP	the spinal cord	15250
@NP	rats -LRB- Fig. 4A and B -RRB-	15269
@NP	rats	15269
@NP	Fig. 4A and B	15274
@NP	Fig. 4A	15274
@NP	B	15286
@NP	The level of NGF protein	15290
@NP	The level	15290
@NP	NGF protein	15303
@NP	determinedby Western blotting	15324
@NP	A significant decrease of the NGF proteinwas	15355
@NP	A significant decrease	15355
@NP	the NGF proteinwas	15381
@NP	co-transplantation group	15409
@NP	thatin OECs or NSCs group , respectively	15454
@NP	thatin OECs	15454
@NP	NSCs group , respectively	15469
@NP	NSCs	15469
@NP	group	15474
@NP	Fig. 4C and D	15495
@NP	Fig. 4C	15495
@NP	D	15507
@NP	Our resultscollectively	15511
@NP	NSCs and OECs	15565
@NP	resultedin	15579
@NP	the level of NGF expression in vivo	15616
@NP	the level	15616
@NP	NGF expression in vivo	15629
@NP	NGF expression	15629
@NP	vivo	15647
@NP	Discussion	15657
@NP	this study	15671
@NP	we	15683
@NP	the efficacy of co-transplantation -LRB- NSCs and OECs -RRB-	15699
@NP	the efficacy	15699
@NP	co-transplantation	15715
@NP	NSCs and OECs	15734
@NP	NSCs	15734
@NP	OECs	15743
@NP	a rat	15752
@NP	spinal cord transection injury	15758
@NP	the possibly underlying mechanism	15798
@NP	we	15847
@NP	transplantation of NSCs with OECs	15860
@NP	transplantation	15860
@NP	NSCs with OECs	15879
@NP	NSCs	15879
@NP	OECs	15889
@NP	the sensoryfunction	15908
@NP	spinal cord injury -LRB- SCI -RRB-	15934
@NP	spinal cord injury	15934
@NP	SCI	15954
@NP	The possible mechanismscould	15960
@NP	OECs	16009
@NP	the NSCs	16026
@NP	transplantation of NSCs with OECs	16047
@NP	transplantation	16047
@NP	NSCs with OECs	16066
@NP	NSCs	16066
@NP	OECs	16076
@NP	effectivelythe expression of NGF	16095
@NP	effectivelythe expression	16095
@NP	NGF	16124
@NP	These findings	16129
@NP	the first	16148
@NP	intothe effect of co-transplanting NSCs and OECs	16169
@NP	intothe effect	16169
@NP	co-transplanting NSCs and OECs	16187
@NP	sensory func-tional improvement	16221
@NP	spinal cord transection	16263
@NP	some new indication for the treatment of SCI	16304
@NP	some new indication	16304
@NP	the treatment of SCI	16328
@NP	the treatment	16328
@NP	SCI	16345
@NP	co-transplantation cell strategy.It	16358
@NP	co-transplantation	16412
@NP	a new effectivestrategy	16441
@NP	the function of NSCs in injured spinal cord afterSCI	16476
@NP	the function	16476
@NP	NSCs in injured spinal cord afterSCI	16492
@NP	NSCs	16492
@NP	injured spinal cord afterSCI	16500
@NP	Previous studies	16530
@NP	transplantation of NSCsinto the injured spinal cords	16566
@NP	transplantation	16566
@NP	NSCsinto the injured spinal cords	16585
@NP	NSCsinto	16585
@NP	the injured spinal cords	16594
@NP	motor function -LSB- 20,21 -RSB-	16633
@NP	motor function	16633
@NP	20,21 -RSB-	16649
@NP	Behavioral studies	16656
@NP	there	16682
@NP	marked sensory functiondifference between NSCs and NSCs/OECs	16693
@NP	marked sensory functiondifference	16693
@NP	NSCs and NSCs/OECs	16735
@NP	Our experiments	16755
@NP	a new strategy	16782
@NP	transplantation of NSCs	16806
@NP	transplantation	16806
@NP	NSCs	16825
@NP	the side effect of OECs	16842
@NP	the side effect	16842
@NP	OECs	16861
@NP	the improvement ofsensory function.NGF	16877
@NP	a mediator of inflammation	16920
@NP	a mediator	16920
@NP	inflammation	16934
@NP	a crucial role inthe generation of pain	16952
@NP	a crucial role inthe generation	16952
@NP	pain	16987
@NP	the development	16996
@NP	thermal andmechanical hyperalgesia in several acute and chronic pain states	17015
@NP	thermal andmechanical hyperalgesia	17015
@NP	several acute and chronic pain states	17053
@NP	1,6,16,17 -RSB-	17091
@NP	rodents	17106
@NP	NGF	17115
@NP	robust , long-lasting mechani-cal and thermal hyperalgesia	17126
@NP	an increased response to stimulusthat	17185
@NP	an increased response	17185
@NP	stimulusthat	17210
@NP	either local or systemic admin-istration -LSB- 8,18,22 -RSB-	17254
@NP	local or systemic admin-istration	17261
@NP	8,18,22 -RSB-	17296
@NP	NGF-antibodies	17324
@NP	tobe potential analgesics -LSB- 4,30 -RSB-	17347
@NP	tobe potential analgesics	17347
@NP	4,30 -RSB-	17374
@NP	NGF	17381
@NP	hyperalgesicbehaviors	17401
@NP	the construction of centralpain circuitry	17447
@NP	the construction	17447
@NP	centralpain circuitry	17467
@NP	the maintenance of sensory function of neu-rons	17493
@NP	the maintenance	17493
@NP	sensory function of neu-rons	17512
@NP	sensory function	17512
@NP	neu-rons	17532
@NP	It	17542
@NP	NGF	17565
@NP	a central role	17575
@NP	painmechanisms	17593
@NP	an attractive opportu-nity	17635
@NP	a completely novel kind of pain therapeutics.Recent work	17673
@NP	a completely novel kind	17673
@NP	pain therapeutics.Recent work	17700
@NP	exogenous administration	17745
@NP	thisneurotrophin	17773
@NP	rodents ' results in the rapid onset of hyper-algesia	17793
@NP	rodents ' results	17793
@NP	rodents '	17793
@NP	the rapid onset of hyper-algesia	17813
@NP	the rapid onset	17813
@NP	hyper-algesia	17832
@NP	selective antagonism of NGF	17850
@NP	selective antagonism	17850
@NP	NGF	17874
@NP	highly effective inanimal models of many pain states that are remarkably free	17881
@NP	highly effective inanimal models	17881
@NP	many pain states that are remarkably free	17917
@NP	many pain states	17917
@NP	ofadverse effects -LSB- 1,2 -RSB-	17959
@NP	ofadverse effects	17959
@NP	1,2 -RSB-	17978
@NP	It	17984
@NP	NGF mRNAcan	18014
@NP	neurons of the DRG	18042
@NP	neurons	18042
@NP	the DRG	18053
@NP	SCI	18067
@NP	the pat-tern of NGF mRNA expression	18076
@NP	the pat-tern	18076
@NP	NGF mRNA expression	18092
@NP	NGF transcriptionmay	18127
@NP	injury	18162
@NP	the central processes of sensoryneurons -LSB- 5 -RSB-	18172
@NP	the central processes	18172
@NP	sensoryneurons -LSB- 5 -RSB-	18197
@NP	sensoryneurons	18197
@NP	5 -RSB-	18213
@NP	our study	18220
@NP	downregulation of the NGF in animalsco-transplanted of NSCs with OECs	18231
@NP	downregulation	18231
@NP	the NGF in animalsco-transplanted of NSCs with OECs	18249
@NP	the NGF	18249
@NP	animalsco-transplanted of NSCs with OECs	18260
@NP	animalsco-transplanted	18260
@NP	NSCs with OECs	18286
@NP	NSCs	18286
@NP	OECs	18296
@NP	a possible rea-son for sensory function improvement	18314
@NP	a possible rea-son	18314
@NP	sensory function improvement	18337
@NP	neuropathicpain.In summary	18380
@NP	our results	18408
@NP	OECs	18434
@NP	NSCssurvival	18453
@NP	vivo	18487
@NP	Co-transplantation NSCs withOECs	18493
@NP	rise	18531
@NP	a significant improvement	18539
@NP	the sensory function , which is associated with the downregulation of NGF	18568
@NP	the sensory function	18568
@NP	the downregulation of NGF	18614
@NP	the downregulation	18614
@NP	NGF	18636
@NP	The presentfindings	18641
@NP	a new strategy	18683
@NP	a bettermolecular understanding on the culture effect	18708
@NP	a bettermolecular understanding	18708
@NP	the culture effect	18743
@NP	the potential for co-transplantation NSCs	18793
@NP	the potential	18793
@NP	co-transplantation NSCs	18811
@NP	OECs inclinical appliction	18840
@NP	OECs	18840
@NP	inclinical appliction	18845
@VP	exhibit neuropathic pain which presents unique challenges to clinicians	1000
@VP	presents unique challenges to clinicians	1031
@VP	is no effective approach for the treatment up to now	1082
@VP	is the low survival of NSCs in traumatic milieu in host spinal cords	1285
@VP	remains elusive	1397
@VP	could promote NSCs survival , and reverses thehyperalgesia triggered by OECs	1834
@VP	could promote NSCs survival	1834
@VP	promote NSCs survival	1840
@VP	reverses thehyperalgesia triggered by OECs	1867
@VP	triggered by OECs	1892
@VP	was corresponding to a significant improvement in sensory function.Moreover	1916
@VP	corresponding to a significant improvement in sensory function.Moreover	1920
@VP	downregulated in the spinal cord of co-transplantation rats.The present findings	2024
@VP	is involved in NGF downregulation in rats with SCI	2214
@VP	involved in NGF downregulation in rats with SCI	2217
@VP	1	2363
@VP	results in paraplegia , orquadriplegia	2412
@VP	are limited	2834
@VP	substitute the damaged cells	2942
@VP	facilitate neuroprotective and neuroregenera-tive repair following SCI	2975
@VP	have the abilityto self-renew	3072
@VP	is far awayfrom practical clinic usage because of its limited survival in vivo	3213
@VP	to increase the survival oftransplanted NSCs in injured spinal cord	3335
@VP	increase the survival oftransplanted NSCs in injured spinal cord	3338
@VP	oftransplanted NSCs in injured spinal cord	3360
@VP	be a better candidate for cell based regener-ative therapies -LSB- 19,23 -RSB-	3514
@VP	based regener-ative therapies -LSB- 19,23 -RSB-	3545
@VP	wereshown to enhance axonal regrowth	3618
@VP	to enhance axonal regrowth	3628
@VP	enhance axonal regrowth	3631
@VP	regulate astrocyte reactivity , increase angiogenesis	3656
@VP	modulate glial scar leading to functionalrecovery	3712
@VP	transplanted into experimental models of SCI inrodents -LSB- 19,25,31,32 -RSB-	3767
@VP	demyelination -LRB- such as chronic multiple sclerosis -RRB- -LSB- 3,15 -RSB-	3934
@VP	-LSB- 13,29 -RSB-	4019
@VP	form cellular bridges to allow axonal regenerationacross the repair site	4671
@VP	to allow axonal regenerationacross the repair site	4693
@VP	allow axonal regenerationacross the repair site	4696
@VP	enhance the survival of damaged axons -LSB- 7,9,26,27 -RSB-	4748
@VP	co-transplanted with NSCs	4846
@VP	were observed afterthe co-transplantation	5093
@VP	observed afterthe co-transplantation	5098
@VP	explored the underlying mecha-nism	5144
@VP	2	5181
@VP	were performed in adult female Sprague-Dawleyrats weighing 180	5231
@VP	performed in adult female Sprague-Dawleyrats weighing 180	5236
@VP	weighing 180	5281
@VP	ranging in age from 90 to 120 days	5301
@VP	derived from the Animal Center of the Si chuan University	5336
@VP	were available ad libitum	5425
@VP	were maintained at 22 ±	5490
@VP	maintained at 22 ±	5495
@VP	was used	5574
@VP	used	5578
@VP	were not informed about the treatment	5667
@VP	informed about the treatment	5676
@VP	werehandled at least three times before any testing was performed	5714
@VP	was performed	5766
@VP	performed	5770
@VP	were divided into five experimental groups	6059
@VP	divided into five experimental groups	6064
@VP	were used for RT-PCR and WB analysis	6127
@VP	used for RT-PCR and WB analysis	6132
@VP	was then processed forimmunohistochemical staining	6277
@VP	processed forimmunohistochemical staining	6286
@VP	were deeply anesthetized with 40 -- 60 mg kg − 1 of pento-barbital i.p.	6381
@VP	turned supine	6452
@VP	were performed under a surgical microscope	6515
@VP	performed under a surgical microscope	6520
@VP	was opened	6567
@VP	opened	6571
@VP	was completely transectedusing sharp sterilized fine scissors	6598
@VP	completely transectedusing sharp sterilized fine scissors	6602
@VP	lifted to ensure complete transection	6695
@VP	to ensure complete transection	6702
@VP	ensure complete transection	6705
@VP	was maintained at 37 ◦ C during the operation.Cell suspensions	6762
@VP	maintained at 37 ◦ C during the operation.Cell suspensions	6766
@VP	maintained on ice for transplan-tation	6949
@VP	completing the lesion	7007
@VP	weredeposited into gelatin then transplanted into injury site	7040
@VP	then transplanted into injury site	7067
@VP	recover spontaneously	7188
@VP	gain access to foodand water at ad libitum in isolated cages	7214
@VP	wereemptied manually twice a day and administrated penicillin for 3days	7296
@VP	wereemptied manually twice a day	7296
@VP	administrated penicillin for 3days	7333
@VP	To reduce the immunoreaction	7369
@VP	reduce the immunoreaction	7372
@VP	was regularly administered twice a day before cell transplantation	7426
@VP	administered twice a day before cell transplantation	7440
@VP	to last for 1 week -LRB- once a day -RRB- till animals were sac-rificed	7507
@VP	last for 1 week -LRB- once a day -RRB- till animals were sac-rificed	7510
@VP	were sac-rificed	7552
@VP	was focused on the dorsal surface of the tail	7857
@VP	focused on the dorsal surface of the tail	7861
@VP	took the rat to withdraw its tail from the noxious stimulus	7925
@VP	to withdraw its tail from the noxious stimulus	7938
@VP	withdraw its tail from the noxious stimulus	7941
@VP	was recorded	7985
@VP	recorded	7989
@VP	were restrained in the rat holder with a tail exitport during the measurement	8008
@VP	restrained in the rat holder with a tail exitport during the measurement	8013
@VP	were performed 5 times -LRB- with a 2-min interval -RRB- at each time point	8097
@VP	performed 5 times -LRB- with a 2-min interval -RRB- at each time point	8102
@VP	to avoid tissue damage in the tail	8230
@VP	avoid tissue damage in the tail	8233
@VP	did not flick by 10 s	8277
@VP	flick by 10 s	8285
@VP	was considered as fully analgesic	8299
@VP	considered as fully analgesic	8303
@VP	were handled for 3 days before testing	8489
@VP	handled for 3 days before testing	8494
@VP	was gently caught and wrapped in a towel during the test	8538
@VP	caught and wrapped in a towel during the test	8549
@VP	was placed between a wedge-shaped blunt piston andplinth	8613
@VP	placed between a wedge-shaped blunt piston andplinth	8617
@VP	was applied via stamped on the pedal	8692
@VP	applied via stamped on the pedal	8696
@VP	stamped on the pedal	8708
@VP	rotating a screw that moved the slide along the scale	8801
@VP	moved the slide along the scale	8823
@VP	terminated the measurement	8938
@VP	was read on the scale -LRB- calibrated in grams -RRB-	8989
@VP	read on the scale -LRB- calibrated in grams -RRB-	8993
@VP	were performed 4 times at 15 sintervals	9081
@VP	performed 4 times at 15 sintervals	9086
@VP	was used for calculations	9137
@VP	used for calculations	9141
@VP	was interpreted as mechanical antinoci-ception	9201
@VP	interpreted as mechanical antinoci-ception	9205
@VP	blinded to the treatment protocol performedall behavioral experiments	9261
@VP	were analyzed usingmean ± SEM	9345
@VP	analyzed usingmean ± SEM	9350
@VP	were performed using the statisticalsoftware SPSS11 .0	9428
@VP	performed using the statisticalsoftware SPSS11 .0	9433
@VP	using the statisticalsoftware SPSS11 .0	9443
@VP	were demonstrated as means ± standarddeviations	9488
@VP	demonstrated as means ± standarddeviations	9493
@VP	± standarddeviations	9515
@VP	was performed when two sets of datawere compared	9555
@VP	performed when two sets of datawere compared	9559
@VP	compared	9595
@VP	were performed	9629
@VP	performed	9634
@VP	assumed	9687
@VP	was used	9696
@VP	used	9700
@VP	was used to denote statistical significance	9730
@VP	used to denote statistical significance	9734
@VP	to denote statistical significance	9739
@VP	denote statistical significance	9742
@VP	3	9776
@VP	Cultured Neurosphere at day 7	9858
@VP	was shown in A -LRB- natural light -RRB- ,	9888
@VP	shown in A -LRB- natural light -RRB- ,	9892
@VP	showed morphology of OECs in vitro	10137
@VP	showed p75 positive OECs	10175
@VP	displayed the nuclear labeled OECs with Hoechst 33342	10203
@VP	labeled OECs with Hoechst 33342	10225
@VP	= 20 µm , showing in I.	10262
@VP	showing in I.	10271
@VP	showed the proliferation of NSCs cultured alone	10356
@VP	cultured alone	10389
@VP	showed the number of the neurosphere with or without co-culturing	10508
@VP	resulted from RT-PCR was shown in A	10743
@VP	was shown in A	10764
@VP	shown in A	10768
@VP	was shownin B.	10810
@VP	decreased NGF mRNA expression than NSCs or OECs grafts , respectively	10844
@VP	was shown in C , indicated from Western blotting	10924
@VP	shown in C , indicated from Western blotting	10928
@VP	indicated from Western blotting	10940
@VP	was shown in D.	10994
@VP	shown in D.	10998
@VP	compared with control group -LRB- NSCs or OECs grafts -RRB- -LRB- * , **	11090
@VP	:p <	11146
@VP	using specific markers , known as nestin and p75 , respectively	11297
@VP	known as nestin and p75 , respectively	11321
@VP	increased	11585
@VP	comprised hundreds of cells at the 7th day of culture -LRB- Fig. 1A and B -RRB-	11609
@VP	were Nestin immunopositive , suggesting that they were NSCs -LRB- Fig. 1C -RRB-	11698
@VP	suggesting that they were NSCs -LRB- Fig. 1C -RRB-	11725
@VP	were NSCs -LRB- Fig. 1C -RRB-	11746
@VP	exhibited some GFAP and a few NeuNor APC immunopositive -LRB- Fig. 1D -- F -RRB-	11814
@VP	were round , widely distributed andstuck to the bottom after 1 day	11905
@VP	widely distributed andstuck to the bottom after 1 day	11917
@VP	shows the dis-play by p75 immunoreactivity	12119
@VP	were also observed	12246
@VP	also observed	12251
@VP	were most abundant	12286
@VP	confirmed that they are OECs -LRB- Fig. 1G and H -RRB-	12403
@VP	are OECs -LRB- Fig. 1G and H -RRB-	12423
@VP	could label these OECs with blue fluorescence , showing inFig	12465
@VP	label these OECs with blue fluorescence , showing inFig	12471
@VP	showing inFig	12512
@VP	co-cultured with OECs	12600
@VP	increased significantly	12688
@VP	co-cultured with OECs	12841
@VP	cultured group -LRB- 109.8 ± 50.5 Pix-els -RRB-	12940
@VP	promote both survival and proliferation of NSCs -LRB- Fig. 2A -- D -RRB-	13114
@VP	decreasedPWL compared with sham one -LRB- p < 0.01 -RRB-	13308
@VP	to decrease PWL compared with SCT one -LRB- p < 0.05 -RRB-	13386
@VP	decrease PWL compared with SCT one -LRB- p < 0.05 -RRB-	13389
@VP	demonstrating that OECs could inducesensory sensitivity in SCT rats , p < 0.01	13852
@VP	could inducesensory sensitivity in SCT rats , p < 0.01	13876
@VP	inducesensory sensitivity in SCT rats , p < 0.01	13882
@VP	onlysubjected to SCT	13950
@VP	showing NSCs grafts is benefit for the improvementof sensory function	14091
@VP	is benefit for the improvementof sensory function	14111
@VP	is no significantdifference between co-transplantation group	14318
@VP	observed by determining the numberof live cells -LRB- green fluorescent -RRB-	14419
@VP	determining the numberof live cells -LRB- green fluorescent -RRB-	14431
@VP	survived	14498
@VP	distributedextensively within spinal cord	14511
@VP	more limitedly beyond thelesion site	14557
@VP	compared with that in only NSCs transplanted group -LRB- Fig	14658
@VP	in only NSCs transplanted group -LRB- Fig	14677
@VP	-RRB-	14716
@VP	was observed in theregions of the lamina I and III	14824
@VP	observed in theregions of the lamina I and III	14828
@VP	was found in the spinal lamina II of the dorsal horn -LRB- Figs	14907
@VP	found in the spinal lamina II of the dorsal horn -LRB- Figs	14911
@VP	To determine the effect of co-transplantation on theexpression of NGF	14978
@VP	determine the effect of co-transplantation on theexpression of NGF	14981
@VP	was performed from samples 2 weeksafter co-transplantation	15056
@VP	performed from samples 2 weeksafter co-transplantation	15060
@VP	was detected in the spinal cord of rats -LRB- Fig. 4A and B -RRB-	15234
@VP	detected in the spinal cord of rats -LRB- Fig. 4A and B -RRB-	15238
@VP	was also determinedby Western blotting	15315
@VP	compared with thatin OECs or NSCs group , respectively -LRB- Fig. 4C and D -RRB-	15440
@VP	decrease in the level of NGF expression in vivo	15604
@VP	4	15654
@VP	modeland the possibly underlying mechanism	15789
@VP	could improve the sensoryfunction after spinal cord injury -LRB- SCI -RRB-	15894
@VP	improve the sensoryfunction after spinal cord injury -LRB- SCI -RRB-	15900
@VP	be associated with	15989
@VP	associated with	15992
@VP	downregulated effectivelythe expression of NGF	16081
@VP	to enhance the function of NSCs in injured spinal cord afterSCI	16465
@VP	enhance the function of NSCs in injured spinal cord afterSCI	16468
@VP	could improve motor function -LSB- 20,21 -RSB-	16619
@VP	improve motor function -LSB- 20,21 -RSB-	16625
@VP	showed there were marked sensory functiondifference between NSCs and NSCs/OECs	16675
@VP	were marked sensory functiondifference between NSCs and NSCs/OECs	16688
@VP	using transplantation of NSCs to withdraw the side effect of OECs	16800
@VP	to withdraw the side effect of OECs	16830
@VP	withdraw the side effect of OECs	16833
@VP	is normally painful	17223
@VP	administrated NGF-antibodies appears tobe potential analgesics -LSB- 4,30 -RSB-	17310
@VP	appears tobe potential analgesics -LSB- 4,30 -RSB-	17339
@VP	plays a central role in painmechanisms	17569
@VP	to develop a completely novel kind of pain therapeutics.Recent work	17662
@VP	develop a completely novel kind of pain therapeutics.Recent work	17665
@VP	is highly effective inanimal models of many pain states that are remarkably free	17878
@VP	are remarkably free	17939
@VP	been demonstrated that NGF mRNAcan be expressed in neurons of the DRG after SCI	17991
@VP	demonstrated that NGF mRNAcan be expressed in neurons of the DRG after SCI	17996
@VP	be expressed in neurons of the DRG after SCI	18026
@VP	expressed in neurons of the DRG after SCI	18029
@VP	be induced by injury to the central processes of sensoryneurons -LSB- 5 -RSB-	18148
@VP	induced by injury to the central processes of sensoryneurons -LSB- 5 -RSB-	18151
@VP	underlie a possible rea-son for sensory function improvement	18305
@VP	decrease neuropathicpain.In summary	18371
@VP	indicate that OECs could promote NSCssurvival both in vitro and in vivo	18420
@VP	could promote NSCssurvival	18439
@VP	promote NSCssurvival	18445
@VP	is associated with the downregulation of NGF	18595
@VP	associated with the downregulation of NGF	18598
@VP	may provide a new strategy	18671
@VP	provide a new strategy	18675
